Overview

Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, syrup, 30 mg/5 ml, in the treatment of influenza or other acute respiratory infections in children from 6 months to 2 years compared with placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Valenta Pharm JSC

Treatments:

Pentanedioic acid imidazolyl ethanamide